Exclusive-Tesla presented misleading ‘Full Self-Driving’ safety data to European regulators

Tesla is facing scrutiny in Europe over allegedly misleading safety statistics used to support approval of its Full Self-Driving system. Reuters says Tesla’s claims, including that FSD could have saved 32,000 lives and prevented 1.9 million injuries, rely on unrealistic comparisons and inflated benchmarks, which may complicate regulatory approvals. The Netherlands has approved FSD for use domestically and is seeking EU-wide approval, but regulators in Sweden and Norway are being urged to look beyond Tesla’s self-produced data.

Analysis

The immediate market read is not just reputational drag for TSLA, but a potential delay in monetizing a key growth lever outside the US. European approval would have been a marginal-demand catalyst rather than a unit-volume step change, but it matters because Tesla’s regional share recovery is increasingly contingent on product differentiation, and FSD is one of the few features with pricing power. If regulators conclude Tesla’s submission methods are systematically biased, the risk is not only slower approval but a tighter evidentiary bar that could force rework across multiple jurisdictions, pushing the monetization window out by quarters.

Second-order, the bigger winner may be OEMs and Tier-1 ADAS suppliers with more conservative claims and cleaner regulatory posture. Tesla’s argument only helps the broader autonomy trade if regulators accept marketing-led validation; if they don’t, competitors can position their systems as less flashy but more certifiable, which is valuable in Europe where legal exposure and type-approval process quality matter more than consumer hype. That also creates a near-term asymmetry: the more Tesla pushes FSD as a demand driver, the more it invites scrutiny that can spill over into safety, disclosure, and governance debates already embedded in the stock’s multiple.

The contrarian view is that this may be more of an execution and timing issue than a fundamental impairment to TSLA’s long-run autonomous option value. Europe’s approval process is still alive, and if a member-state coalition eventually signs off, the narrative can flip quickly because investors will price in subscription attach-rate upside long before meaningful revenue is visible. But the path dependency is worsening: each regulatory challenge increases the probability that Tesla has to discount FSD, bundle it, or accept a slower rollout, which reduces the option premium embedded in the equity.

Key Decisions for Investors

• Reduce TSLA into strength over the next 1-2 weeks; the market is likely to overestimate the near-term Europe option value, while the regulatory overhang can compress multiple expansion by 5-10% if headlines worsen.
• Buy TSLA put spreads 1-3 months out, sized for a catalyst-driven move lower if European regulators formalize a higher evidence threshold; attractive if implied vol remains below event risk.
• Pair trade: short TSLA / long a diversified ADAS or autonomy beneficiary with cleaner regulatory optics over 3-6 months; thesis is that the market will reward certifiability over narrative as EU scrutiny intensifies.
• For event traders, sell covered calls against existing TSLA longs into any approval-related bounce; the upside from Europe is likely incremental, while downside from governance/regulatory headlines is more convex.
• Avoid chasing RDW as a standalone long; any benefit is mostly institutional credibility, not earnings leverage, and the trade is likely to mean-revert once the approval process becomes more cumbersome.